Developer docs
API playgroundTry for free, no card

Search company profiles

EsoCap

Full company profile

uuid000ck8d

Namestring
EsoCap
Legal namestring
EsoCap AG
Company typeenum
Private
Founded yearint
2017
Descriptiontext

EsoCap AG is a Swiss clinical-stage biotechnology company founded in 2017 and headquartered in Basel. It develops therapies for patients with diseases of the esophagus, with its lead product, ESO-101, in development for eosinophilic esophagitis (EoE). The Phase II ACESO trial was reported as successful and statistically significant with p=0.0318, and ESO-101 received FDA Orphan Drug Designation.

The company's core technology is a swallowable application system that places a thin, degradable, drug-loaded mucoadhesive film directly on the esophageal mucosa. This design is intended to provide localized, sustained drug exposure in the upper gastrointestinal tract, where conventional oral and injectable therapies can have difficulty achieving sufficient local exposure. EsoCap also reports development work involving 3D-printed films, hot-melt-extrusion fiber production, and delivery of RNA and biologics, although no additional clinical-stage product is identified.

EsoCap is pre-revenue and has a reported team of 1–10 employees. Its disclosed network includes LTS Lohmann and Lonza for manufacturing, Zühlke Engineering for an automated assembly-line prototype, FGK Clinical Research, and the University of Greifswald, from which the underlying technology was licensed. The platform has patents granted in more than 13 jurisdictions and a CE-certified application device; the available data do not disclose commercial pricing, product sales, licensing income, or a finalized go-to-market model.

Short descriptiontext

EsoCap AG is a Swiss clinical-stage biotechnology company developing a mucoadhesive film platform for localized treatment of esophageal diseases. Its lead product, ESO-101, targets eosinophilic esophagitis and completed a statistically significant Phase II trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
esophageal drug delivery, mucoadhesive film technology, eosinophilic esophagitis treatment, targeted local therapy, biopharmaceutical drug development
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
Product category
Drug Delivery Technology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Licensing
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotech pursuing licensing partnerships with pharmaceutical companies for commercialization of ESO-101 and the EsoCap platform technology. Revenue model will likely involve upfront payments, milestone payments, and royalties upon regulatory approval and commercialization.

esocapbiotech.ch
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

EsoCap develops a proprietary mucoadhesive film drug delivery platform packaged inside a swallowable capsule to enable targeted, long-lasting local therapy of the esophagus. The capsule deploys a thin, API-loaded film that adheres to the esophageal mucosa for 15+ minutes, allowing topical treatment of esophageal diseases for the first time. Its lead drug candidate, ESO-101, delivers mometasone furoate via this platform for once-daily treatment of eosinophilic esophagitis (EoE) and has successfully completed a Phase II trial (ACESO).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Statistically significant reduction in peak eosinophil count (p=0.0318) compared to placebo in Phase II ACESO trial
+2 more records
Product overview1 text field

EsoCap AG is a Swiss biotech company pioneering an innovative drug delivery platform for the world's first local treatment of the esophagus. The core offering consists of the EsoCap System, a platform technology that uses a capsule containing a thin mucoadhesive film to achieve targeted, long-lasting drug delivery to the esophageal mucosa. The lead product candidate, ESO-101, applies mometasone furoate via this platform for the treatment of eosinophilic esophagitis (EoE). The platform technology has demonstrated versatility by successfully incorporating small molecules, peptides, antibodies, and liposomal encapsulated RNA. The completed ACESO Phase II clinical trial validated the safety and efficacy of ESO-101, with results published in Alimentary Pharmacology & Therapeutics.

Product and service1 record
1ESO-101
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-06-26
Description

Developed prototype automated assembly line for EsoCap's manufacturing process. Zühlke engineers used virtual reality (VR) and 3D printing technologies to efficiently develop a production line capable of manufacturing millions of EsoCaps per year.

Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2021-03-30
Description

Contract Research Organization that partnered with EsoCap for the ACESO Phase II clinical trial, providing clinical operations support across 14 clinics in 5 European countries.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2020-02-28
Description

Manufacturer of injection-molded plastic elements for EsoCap's application device. Successfully fulfilled obligations towards Swissmedic and EU requirements for medical device production.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-02-20
Description

Industrial development collaboration for manufacturing clinical trial samples. LTS is a leading pharmaceutical technology company developing and manufacturing innovative thin film drug delivery systems with over 20 marketed products and 30+ pipeline projects. Collaboration leverages LTS's thin film expertise with EsoCap's innovative application technology.

5University of Greifswald
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-07-28
Description

Exclusive worldwide licensing agreement for the unique drug delivery technology developed by Prof. Werner Weitschies and his team at the Center of Drug Absorption and Transport. The university developed the core EsoCap technology including the mucoadhesive film system and EsoPeriDiss release model. Ongoing collaboration on research including 3D-printed films, hot-melt extrusion, and RNA drug delivery development.

esocapbiotech.ch
Strategic tierSupportingTypeTechnology or Integration
Description

Lonza's Capsules & Health Ingredients business provides innovative capsule solutions and dosage form expertise. Lonza serves over 5,000 customers in 100+ countries and brings capsule polymer science expertise for optimizing bioavailability and targeted delivery.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Specialty pharmaceutical company with proprietary drug delivery technologies (including buccal film technology). Comparable in its focus on novel drug delivery platforms to enable localized drug administration.

TypeBroad incumbent
Description

Global pharmaceutical company with an approved EoE therapy (budesonide oral suspension) and established gastroenterology franchise. Represents the primary incumbent EsoCap would compete against in EoE.

3Allakos
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapeutics for eosinophilic gastrointestinal diseases including EoE. A direct comparable in terms of indication focus and clinical-stage biotech profile.

TypeDirect peer
Description

Specialty pharmaceutical company focused on EoE and GI drug delivery, with an approved EoE therapy (budesonide oral suspension). Highly comparable to EsoCap given shared EoE focus and emphasis on localized/topical GI delivery.

TypeBroad incumbent
Description

Biopharmaceutical companies with Dupixent (dupilumab) approved for EoE. A major incumbent competitor with established commercial infrastructure and physician relationships in the EoE market.

TypeEmerging player
Description

EoE-focused biotech developing targeted therapies for eosinophilic esophagitis. Comparable to EsoCap in indication focus and stage, though with different therapeutic modalities.

TypeBroad incumbent
Description

Drug delivery platform company with proprietary ENHANZE technology for subcutaneous drug delivery. Comparable in its platform-based drug delivery approach and licensing/royalty business model.

TypeEmerging player
Description

GI-focused specialty pharmaceutical company developing treatments for gastric acid-related disorders. Comparable in its focus on underserved GI conditions and specialty pharma commercial model.

TypeBroad incumbent
Description

GI-focused pharmaceutical company with commercial-stage products in gastrointestinal disorders. Comparable in its GI therapeutic focus and specialty pharma commercial approach.

TypeEmerging player
Description

Specialty biopharmaceutical company focused on gastrointestinal diseases. Comparable in its GI therapeutic focus and commercialization model for underserved GI conditions.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EsoCap

Drug Delivery Technologyesocapbiotech.ch

EsoCap AG is a Swiss clinical-stage biotechnology company developing a mucoadhesive film platform for localized treatment of esophageal diseases. Its lead product, ESO-101, targets eosinophilic esophagitis and completed a statistically significant Phase II trial.

What EsoCap does

EsoCap AG is a Swiss clinical-stage biotechnology company founded in 2017 and headquartered in Basel. It develops therapies for patients with diseases of the esophagus, with its lead product, ESO-101, in development for eosinophilic esophagitis (EoE). The Phase II ACESO trial was reported as successful and statistically significant with p=0.0318, and ESO-101 received FDA Orphan Drug Designation.

The company's core technology is a swallowable application system that places a thin, degradable, drug-loaded mucoadhesive film directly on the esophageal mucosa. This design is intended to provide localized, sustained drug exposure in the upper gastrointestinal tract, where conventional oral and injectable therapies can have difficulty achieving sufficient local exposure. EsoCap also reports development work involving 3D-printed films, hot-melt-extrusion fiber production, and delivery of RNA and biologics, although no additional clinical-stage product is identified.

EsoCap is pre-revenue and has a reported team of 1–10 employees. Its disclosed network includes LTS Lohmann and Lonza for manufacturing, Zühlke Engineering for an automated assembly-line prototype, FGK Clinical Research, and the University of Greifswald, from which the underlying technology was licensed. The platform has patents granted in more than 13 jurisdictions and a CE-certified application device; the available data do not disclose commercial pricing, product sales, licensing income, or a finalized go-to-market model.

EsoCap firmographics

Firmographics
Name
EsoCap
Legal name
EsoCap AG
Website
https://esocapbiotech.ch
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
EsoCap AG is a Swiss clinical-stage biotechnology company developing a mucoadhesive film platform for localized treatment of esophageal diseases. Its lead product, ESO-101, targets eosinophilic esophagitis and completed a statistically significant Phase II trial.
Ownership category
akta.pro rank

Where EsoCap is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

EsoCap business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Licensing: Pre-revenue clinical-stage biotech pursuing licensing partnerships with pharmaceutical companies for commercialization of ESO-101 and the EsoCap platform technology. Revenue model will likely involve upfront payments, milestone payments, and royalties upon regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

EsoCap product offering

Product offering

Core offering

EsoCap develops a proprietary mucoadhesive film drug delivery platform packaged inside a swallowable capsule to enable targeted, long-lasting local therapy of the esophagus. The capsule deploys a thin, API-loaded film that adheres to the esophageal mucosa for 15+ minutes, allowing topical treatment of esophageal diseases for the first time. Its lead drug candidate, ESO-101, delivers mometasone furoate via this platform for once-daily treatment of eosinophilic esophagitis (EoE) and has successfully completed a Phase II trial (ACESO).

Product overview

EsoCap AG is a Swiss biotech company pioneering an innovative drug delivery platform for the world's first local treatment of the esophagus. The core offering consists of the EsoCap System, a platform technology that uses a capsule containing a thin mucoadhesive film to achieve targeted, long-lasting drug delivery to the esophageal mucosa. The lead product candidate, ESO-101, applies mometasone furoate via this platform for the treatment of eosinophilic esophagitis (EoE). The platform technology has demonstrated versatility by successfully incorporating small molecules, peptides, antibodies, and liposomal encapsulated RNA. The completed ACESO Phase II clinical trial validated the safety and efficacy of ESO-101, with results published in Alimentary Pharmacology & Therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • ESO-101

Quantifiable outcome

  • Statistically significant reduction in peak eosinophil count (p=0.0318) compared to placebo in Phase II ACESO trial
  • +2 more outcomes

Companies that use EsoCap

Customer profile

Segments2 records

Ideal customer profiles2 records

EsoCap technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

EsoCap partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered supporting and core.

  • Zühlke EngineeringsupportingImplementation/ SI/ Consulting Partner · 26 June 2023Developed prototype automated assembly line for EsoCap's manufacturing process. Zühlke engineers used virtual reality (VR) and 3D printing technologies to efficiently develop a production line capable of manufacturing millions of EsoCaps per year.
  • FGK CROsupportingImplementation/ SI/ Consulting Partner · 30 March 2021Contract Research Organization that partnered with EsoCap for the ACESO Phase II clinical trial, providing clinical operations support across 14 clinics in 5 European countries.
  • Hänggli Thermoplast AGsupportingTechnology or Integration · 28 February 2020Manufacturer of injection-molded plastic elements for EsoCap's application device. Successfully fulfilled obligations towards Swissmedic and EU requirements for medical device production.
  • LTS Lohmann Therapy-Systeme AGcoreStrategic or Co-development Partner · 20 February 2019Industrial development collaboration for manufacturing clinical trial samples. LTS is a leading pharmaceutical technology company developing and manufacturing innovative thin film drug delivery systems with over 20 marketed products and 30+ pipeline projects. Collaboration leverages LTS's thin film expertise with EsoCap's innovative application technology.
  • University of GreifswaldcoreStrategic or Co-development Partner · 28 July 2017Exclusive worldwide licensing agreement for the unique drug delivery technology developed by Prof. Werner Weitschies and his team at the Center of Drug Absorption and Transport. The university developed the core EsoCap technology including the mucoadhesive film system and EsoPeriDiss release model. Ongoing collaboration on research including 3D-printed films, hot-melt extrusion, and RNA drug delivery development.
  • LonzasupportingTechnology or IntegrationLonza's Capsules & Health Ingredients business provides innovative capsule solutions and dosage form expertise. Lonza serves over 5,000 customers in 100+ countries and brings capsule polymer science expertise for optimizing bioavailability and targeted delivery.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

EsoCap competitors and assessment

Company assessment

Emerging players

  • BioDelivery Sciences International: Specialty pharmaceutical company with proprietary drug delivery technologies (including buccal film technology). Comparable in its focus on novel drug delivery platforms to enable localized drug administration.
  • Ellodi Pharmaceuticals: EoE-focused biotech developing targeted therapies for eosinophilic esophagitis. Comparable to EsoCap in indication focus and stage, though with different therapeutic modalities.
  • Phathom Pharmaceuticals: GI-focused specialty pharmaceutical company developing treatments for gastric acid-related disorders. Comparable in its focus on underserved GI conditions and specialty pharma commercial model.
  • RedHill Biopharma: Specialty biopharmaceutical company focused on gastrointestinal diseases. Comparable in its GI therapeutic focus and commercialization model for underserved GI conditions.

Broad incumbents

  • Takeda Pharmaceutical: Global pharmaceutical company with an approved EoE therapy (budesonide oral suspension) and established gastroenterology franchise. Represents the primary incumbent EsoCap would compete against in EoE.
  • Sanofi / Regeneron: Biopharmaceutical companies with Dupixent (dupilumab) approved for EoE. A major incumbent competitor with established commercial infrastructure and physician relationships in the EoE market.
  • Halozyme Therapeutics: Drug delivery platform company with proprietary ENHANZE technology for subcutaneous drug delivery. Comparable in its platform-based drug delivery approach and licensing/royalty business model.
  • Ironwood Pharmaceuticals: GI-focused pharmaceutical company with commercial-stage products in gastrointestinal disorders. Comparable in its GI therapeutic focus and specialty pharma commercial approach.

Direct peers

  • Allakos: Clinical-stage biopharmaceutical company developing therapeutics for eosinophilic gastrointestinal diseases including EoE. A direct comparable in terms of indication focus and clinical-stage biotech profile.
  • Adare Pharmaceuticals: Specialty pharmaceutical company focused on EoE and GI drug delivery, with an approved EoE therapy (budesonide oral suspension). Highly comparable to EsoCap given shared EoE focus and emphasis on localized/topical GI delivery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

EsoCap social profiles

Digital presence

EsoCap compliance and trust

Trust signal

Compliance3 records

EsoCap financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EsoCap leadership team

Management profile

Number of profiles

Profiles6 records

EsoCap funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EsoCap M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EsoCap

What does EsoCap do?

EsoCap develops a proprietary mucoadhesive film drug delivery platform packaged inside a swallowable capsule to enable targeted, long-lasting local therapy of the esophagus. The capsule deploys a thin, API-loaded film that adheres to the esophageal mucosa for 15+ minutes, allowing topical treatment of esophageal diseases for the first time. Its lead drug candidate, ESO-101, delivers mometasone furoate via this platform for once-daily treatment of eosinophilic esophagitis (EoE) and has successfully completed a Phase II trial (ACESO).

Is EsoCap a public or private company?

EsoCap is a private company. It is classified as venture growth investor backed and is currently operating.

When was EsoCap founded?

EsoCap was founded in 2017. It employs 1 to 10 people.

Where is EsoCap based?

EsoCap is headquartered in Basel, Switzerland, in the Europe region.

How does EsoCap make money?

One revenue line is on record: pharmaceutical Product Licensing.

Who are EsoCap's main competitors?

Emerging players on record are BioDelivery Sciences International, Ellodi Pharmaceuticals, Phathom Pharmaceuticals and RedHill Biopharma. Broad incumbents are Takeda Pharmaceutical, Sanofi / Regeneron, Halozyme Therapeutics and Ironwood Pharmaceuticals. Direct peers are Allakos and Adare Pharmaceuticals.

Does EsoCap have an API?

No public API is recorded for EsoCap.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEosinophilic Esophagitis Market: Rapid Increment Driven by Innovation by 2034 - DelveInsight | Regeneron Pharma, Sanofi, Bristol-Myers Squibb, Ellodi Pharma, AstraZeneca, Allakos, EsoCap, PfizerThe article discusses the growth forecast for the Eosinophilic Esophagitis market up to 2034, with key players like Regeneron Pharma, Sanofi, and Pfizer involved in the development of therapies. It highlights the market size projections, recent clinical advances, and regulatory approvals including the FDA's approval of dupilumab for pediatric patients.GlobeNewswireEosinophilic Esophagitis Market to Show Positive Growth by 2032, Examines DelveInsight | Key Companies - Bristol Myers Squibb, Ellodi, AstraZeneca, Kyowa Kirin, Allakos, Pfizer, Revolo, EsoCap AG, NexDelveInsight forecasts the eosinophilic esophagitis market in the 7MM to grow at a significant CAGR to reach USD 10.5 billion by 2032. In 2021, over 727,000 prevalent cases were diagnosed in the 7MM, with the United States having the highest number. Emerging therapies such as Cendakimab and Benralizumab are expected to drive growth.BioSpaceEsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagusEsoCap AG hosted a multidisciplinary advisory board meeting in Zurich on Barrett's esophagus, where experts praised its topical drug delivery technology. The company's Phase II trial for eosinophilic esophagitis is ongoing, with results expected by early 2023.GlobeNewswireEsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagusEsoCap AG held a multidisciplinary advisory board meeting in Zurich with eight experts on Barrett's esophagus, where its topical drug delivery technology was praised for increasing mucosal contact time. The company's Phase II trial for eosinophilic esophagitis is ongoing, with results expected by early 2023.GlobeNewswireEsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagusEsoCap and Upadia signed a worldwide exclusive licensing agreement to develop therapeutics for Barrett's esophagus, combining Upadia's monoclonal antibodies with EsoCap's topical drug delivery technology. The antibodies target BMP2 and BMP4, which regulate Barrett's epithelium, and the collaboration aims to advance clinical development.startupticker.chEsoCap obtains funding as Phase II study progressesEsoCap secured fresh capital from existing and new investors to support the progression of its Phase II clinical study for ESO-101, following the dosing of the first patient. The funding, facilitated by a loan guarantee program from the Canton of Basel-Stadt, will be used to scale industrial activities and expand the technology platform for treating esophageal diseases like Eosinophilic esophagitis. The ongoing trial involves 42 adult patients across four European countries to evaluate the efficacy and safety of the mucoadhesive film drug delivery system.GlobeNewswireEsoCap secures new fundingEsoCap AG closed a private financing round with existing and new investors, facilitated by a subordinated loan guarantee from the Canton of Basel-Stadt. The funds will support the ACESO phase II clinical study for eosinophilic esophagitis and industrial scale-up. The company also plans to explore feasibility for other esophageal diseases.GlobeNewswireEsoCap – unique targeted application platform to treat the upper gastrointestinal tractEsoCap AG announced its targeted application platform for esophageal drug delivery, which increases mucosal contact time to at least 15 minutes. A proof-of-principle trial with 12 volunteers showed the film attached correctly, and a Phase II trial for Eosinophilic Esophagitis is underway. The lead candidate ESO-101 has FDA Orphan Drug Designation.